These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37972660)

  • 21. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
    J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
    Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
    Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
    J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
    Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
    Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma.
    Patel R; Elghawy O; Gibbs A; Gupta S; Kaur V
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2110. PubMed ID: 39051557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.
    Brown TJ; Mamtani R; Gimotty PA; Karasic TB; Yang YX
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2345-2354. PubMed ID: 36862158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
    Cheon J; Jung S; Kim JS; Kang B; Kim H; Chan LL; Becker L; Gaillard VE; Chan SL; Kim C; Chon HJ
    Liver Int; 2024 Aug; 44(8):1961-1970. PubMed ID: 38618972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Simmons DJ; Valerio SJ; Thomas DS; Healey MJ; Jiang Z; Levingston Mac Leod JM; Lin Y; Sah J
    Adv Ther; 2024 Apr; 41(4):1711-1727. PubMed ID: 38443649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
    Villalobos A; Dabbous HH; Little O; Gbolahan OB; Akce M; Lilly MA; Bercu Z; Kokabi N
    Curr Oncol; 2023 Nov; 30(12):10100-10110. PubMed ID: 38132368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma.
    Pomej K; Balcar L; Sidali S; Sartoris R; Meischl T; Trauner M; Mandorfer M; Reiberger T; Ronot M; Bouattour M; Pinter M; Scheiner B
    United European Gastroenterol J; 2024 Oct; 12(8):1034-1043. PubMed ID: 38990728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
    Ning T; Li D; Deng T; Bai Y; Chen Y; Wang Z; Hu B; Ba Y; Lu W
    Cancer; 2024 Sep; 130(18):3137-3146. PubMed ID: 38781433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y
    Cancer Med; 2023 Apr; 12(7):7772-7783. PubMed ID: 36518086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.